1. Home
  2. ZG vs GMAB Comparison

ZG vs GMAB Comparison

Compare ZG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZG

Zillow Group Inc.

HOLD

Current Price

$39.99

Market Cap

16.4B

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$28.25

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZG
GMAB
Founded
2004
1999
Country
United States
Denmark
Employees
N/A
3029
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.4B
16.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZG
GMAB
Price
$39.99
$28.25
Analyst Decision
Buy
Strong Buy
Analyst Count
26
8
Target Price
$79.82
$39.81
AVG Volume (30 Days)
1.0M
1.5M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.77
$18.09
Revenue Next Year
$13.25
$14.82
P/E Ratio
$499.11
$1.90
Revenue Growth
N/A
N/A
52 Week Low
$39.14
$18.89
52 Week High
$90.22
$35.43

Technical Indicators

Market Signals
Indicator
ZG
GMAB
Relative Strength Index (RSI) 37.35 58.02
Support Level N/A $28.17
Resistance Level $46.76 $29.86
Average True Range (ATR) 2.00 0.61
MACD 0.15 0.41
Stochastic Oscillator 10.13 88.14

Price Performance

Historical Comparison
ZG
GMAB

About ZG Zillow Group Inc.

Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Premier Agent and others.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: